During a recent meeting of the New Hampshire House Special Committee on COVID Response Efficacy, significant concerns were raised regarding the safety and efficacy of mRNA vaccines, particularly in relation to potential cancer-promoting sequences and the implications of natural immunity following COVID-19 infection.

One of the key discussions centered around the presence of SV40, a viral sequence that some experts suggest could act as a cancer promoter. Questions were posed about whether this issue is specific to certain vaccine manufacturers or if it is a commonality across all mRNA vaccines. The conversation highlighted a lack of transparency in the vaccine development process, with claims that critical information was omitted from initial filings. This has led to concerns about the manufacturing processes used to produce billions of vaccine doses, raising questions about the potential for contaminants.

The committee also explored the topic of natural immunity, with one member sharing a personal account of severe COVID-19 illness and subsequent hospitalization. This prompted a discussion about the effectiveness of vaccines for individuals who have already contracted the virus. It was noted that there is limited data supporting the necessity of vaccination post-infection, with some physicians expressing skepticism about the safety of administering vaccines to those with natural immunity.

The emergence of the Omicron variant was another focal point, as it demonstrated a different lineage from previous strains, leading to reinfections among those who had previously recovered from COVID-19. This raised further questions about the effectiveness of both natural immunity and vaccines against evolving variants.

The meeting concluded with a call for more rigorous scrutiny of laboratory practices related to viral research, particularly concerning gain-of-function studies. The discussions underscored the need for ongoing investigation into the long-term effects of vaccines and the importance of transparency in public health communications.

As the committee continues its work, the implications of these discussions could influence future vaccine policies and public health strategies in New Hampshire and beyond.